PRLD - Prelude Therapeutics Incorporated

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
1.31 0.04 (3.05%)	---	---	---	---	0.04 (3.05%)	---	---

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Category: PHARMACEUTICAL PREPARATIONS

Market Period: Closed

Earnings & Ratios

Basic EPS:: -0.41
Diluted EPS:: -0.41
Basic P/E:: -3.2927
Diluted P/E:: -3.2927
RSI(14) 1m:: 42.31
VWAP:: 1.36
RVol:: 0.7161

Events

Period	Kind	Movement	Occurred At
1m	Price decrease 1m	1.35 -0.02 (-1.46%)	Oct 15 15:59
1m	Price increase 1m	1.37 +0.01 (+1.11%)	Oct 15 15:53
1m	Price decrease 1m	1.36 -0.02 (-1.45%)	Oct 15 15:50
1m	Price decrease 1m	1.38 -0.02 (-1.43%)	Oct 15 15:49
1m	Price decrease 1m	1.36 -0.02 (-1.45%)	Oct 15 15:37